Compare WILC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | BWAY |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Food Distributors | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.3M | 451.2M |
| IPO Year | 1997 | 2019 |
| Metric | WILC | BWAY |
|---|---|---|
| Price | $28.38 | $25.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $26.50 |
| AVG Volume (30 Days) | 14.8K | ★ 119.9K |
| Earning Date | 03-10-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | 64.86 | ★ 213.09 |
| EPS | ★ 2.05 | 0.13 |
| Revenue | ★ $180,746,882.00 | $49,094,000.00 |
| Revenue This Year | N/A | $330.76 |
| Revenue Next Year | N/A | $22.24 |
| P/E Ratio | ★ $14.06 | $77.54 |
| Revenue Growth | 4.22 | ★ 27.08 |
| 52 Week Low | $12.54 | $7.84 |
| 52 Week High | $30.89 | $25.16 |
| Indicator | WILC | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 70.38 |
| Support Level | $29.04 | $22.90 |
| Resistance Level | $29.63 | $24.78 |
| Average True Range (ATR) | 0.85 | 1.23 |
| MACD | -0.23 | 0.07 |
| Stochastic Oscillator | 61.43 | 97.17 |
G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.